Ko, Emily R.
Reller, Megan E.
Tillekeratne, L. Gayani
Bodinayake, Champica K.
Miller, Cameron
Burke, Thomas W.
Henao, Ricardo
McClain, Micah T.
Suchindran, Sunil
Nicholson, Bradly
Blatt, Adam
Petzold, Elizabeth
Tsalik, Ephraim L.
Nagahawatte, Ajith
Devasiri, Vasantha
Rubach, Matthew P.
Maro, Venance P.
Lwezaula, Bingileki F.
Kodikara-Arachichi, Wasantha
Kurukulasooriya, Ruvini
De Silva, Aruna D.
Clark, Danielle V.
Schully, Kevin L.
Madut, Deng
Dumler, J. Stephen
Kato, Cecilia
Galloway, Renee
Crump, John A.
Ginsburg, Geoffrey S.
Minogue, Timothy D.
Woods, Christopher W.
Funding for this research was provided by:
US Army Medical Research and Materiel Command (W81XWH-16-C-0147)
US NIH NIAID (R01TW009237)
Article History
Received: 27 December 2022
Accepted: 11 December 2023
First Online: 18 December 2023
Competing interests
: CWW is a consultant for Biomeme, Arena Pharmaceuticals, Biofire, FHI Clinical and sits on the advisory board for Biomeme, FHI Clinical, and Regeneron. CWW is also the acting Chief Medical Officer for Biomeme. CWW is a member of the board of directors for Global Health Innovation Alliance Accelerator. TWB hold equity in and is consultant for Biomeme. ELT consults for Biomeme and is employed by Danaher Diagnostics. CWW, ELT, MTM, TWB, and RH hold patents on genomic methods to diagnose and treat acute infections. All other authors reported no conflicts of interest.